Overview

* Cronos ( CRON ) Q3 revenue of $36.3 mln missed analyst expectations

* Adjusted EBITDA of $5.7 mln in Q3 beat analyst estimates

* Company achieved record net revenue in Israel, driven by PEACE NATURALS brand

Outlook

* Cronos ( CRON ) expects Cronos GrowCo expansion to fuel growth in 2026

* Company anticipates international revenue alignment in second-half 2025

* Cronos ( CRON ) plans to continue expanding globally and investing in innovation

Result Drivers

* ISRAEL PERFORMANCE - Record net revenue in Israel driven by PEACE NATURALS brand, maintaining its position as the leading cannabis brand in the country

* CANADIAN MARKET - Increased cannabis extract sales in Canada, although flower sales were constrained, contributing to revenue growth

* COST DISCIPLINE - Improved gross profit due to lower inventory step-up costs and strategic sales mix shift to higher-margin regions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $36.30 $37.30

Revenue mln mln (1

Analyst)

Q3 Net $28.30

Income mln

Q3 Beat $5.70 $5.60

Adjusted mln mln (1

EBITDA Analyst)

Q3 Gross $18.30

Profit mln

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* The stock recently traded at 55 times the next 12-month earnings vs. a P/E of 93 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)